1. Aquilonius SM, Langstrom B, Tedroff J (1989) Brain dopaminergic mechanisms in Parkinson’s disease evaluated by positron emission tomography. Acta Neurol Scand 126:55–59.
2. Calne DB, Langston JW, Martin WR, Stoessl AJ, Ruth TJ, Adam MJ, Pate BD, Schulzer M (1985) Positron emission tomography after MPTP: observations relating to the cause of Parkinson’s disease. Nature 317:246–8.
3. Carlsson A, Lindquist M (1962) In-vivo decarboxylation of a-methyl dopa and α-methyl metatyrosine. Acta Physiol Scand 54:87–94.
4. Chiueh CC, Zukowska-Grojec Z, Kirk KL, Kopin IJ (1983) 6-Fluorocatecholamines as false adrenergic transmitters. J Pharmacol Exp Ther 225:529–533.
5. Chiueh CC, Firnau G, Burns RS, Nahmias C, Kopin IJ, Garnett ES (1987) Determination and visualization of damage to striatal dopaminergic terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by [18-F]-labeled 6-fluoro-L-dopa and positron emission tomography. Adv Neurol 45:167–169.